IGHE and atopic eczema: In patients with comorbid atopic dermatitis, elevated IgE was the strongest biomarker determinant of first‐line dupilumab prescription (OR 8.77, p < 0.001), whereas in patients without, it was elevated FeNO (OR 1.76, p = 0.03).